

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07K 7/00, 7/64, A61K 37/00 A61K 37/38		A1	(11) International Publication Number: WO 94/11393 (43) International Publication Date: 26 May 1994 (26.05.94)
(21) International Application Number: PCT/US93/10662 (22) International Filing Date: 5 November 1993 (05.11.93) (30) Priority data: 07/973,989 9 November 1992 (09.11.92) US (71) Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US). (72) Inventors: KOERBER, Steven, C. ; 818 Nardo Road, Encinitas, CA 92024 (US). PORTER, John, S. ; 1002 Saxony Street, Leucadia, CA 92024 (US). RIVIER, Jean, E., F. ; 9674 Blackgold Road, La Jolla, CA 92037 (US).		(74) Agents: SAMPLES, Kenneth, H. et al.; Fitch, Even, Tabin & Flannery, Room 900, 135 South LaSalle Street, Chicago, IL 60603 (US). (81) Designated States: AU, CA, HU, JP, KR, NZ. European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.	
DOC			

(54) Title: BICYCLIC GnRH ANTAGONISTS

(57) Abstract

Peptides which have substantial bioactivity to inhibit the secretion of gonadotropins by the pituitary gland and to inhibit the release of steroids by the gonads. Administration of an effective amount of such GnRH antagonists prevents ovulation and/or the release of steroids by the gonads. They may also be used to treat steroid-dependent tumors, such as prostatic and mammary tumors. The peptides are bicyclic analogs of the decapeptide GnRH having two covalent bonds, between the residues in the 4- and 10-positions and the residues in the 5- and 8-positions. The latter linkage includes peptide bonds between a residue of an α -amino acid outside of the main chain and a side-chain carboxyl group of the 5-position residue and a side-chain amino group of the 8-position residue.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TC	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

BICYCLIC GnRH ANTAGONISTS

This invention was made with Government support
5 under grant number HD-13527 and contracts NO1-HD-1-3100
and NO1-HD-0-2906 awarded by the National Institutes of
Health. The Government has certain rights in this
invention.

The present invention relates to synthetic
10 peptides containing D-isomers which have biological
properties antagonistic to GnRH and which inhibit the
release of gonadotropins by the pituitary gland in
mammalians, including humans. It also relates to methods
of preventing ovulation and/or inhibiting the release of
15 steroids. More particularly, the present invention is
directed to peptides which inhibit gonadal function and
the release of the steroidal hormones, progesterone and
testosterone.

20

BACKGROUND OF THE INVENTION

The pituitary gland is attached by a stalk to
the region in the base of the brain known as the
hypothalamus. In particular, follicle stimulating
hormone (FSH) and luteinizing hormone (LH), sometimes
25 referred to as gonadotropins or gonadotropic hormones,
are released by the pituitary gland. These hormones, in
combination, regulate the functioning of the gonads to
produce testosterone in the testes and progesterone and
estrogen in the ovaries, and they also regulate the
30 production and maturation of gametes.

The release of a hormone by the anterior lobe of
the pituitary gland usually requires a prior release of
another class of hormones produced by the hypothalamus.
One of the hypothalamic hormones acts as a factor that
35 triggers the release of the gonadotropic hormones,
particularly LH, and this hormone is referred to herein

-2-

as GnRH although it has also been referred to as LH-RH and as LRF. GnRH was isolated and characterized as a decapeptide some 20 years ago, and it was found that analogs of GnRH having a D-isomer instead of Gly in the 6-position, such as [D-Ala⁶]-GnRH (U.S. Patent No. 4,072,668) having the following formula:

pGlu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH₂,
have greater binding strength to the receptor and greater biological potency than the native hormone.

10 Peptides are compounds which contain two or more amino acids in which the carboxyl group of one acid is linked to the amino group of an adjacent acid. The formula for the GnRH analog as represented above is in accordance with conventional representation of peptides
15 where the amino terminus appears to the left and the carboxyl terminus to the right. The position of a particular amino acid residue is identified by numbering the amino acid residues from left to right. In the case of GnRH, the hydroxyl portion of the carboxyl group of
20 glycine at the C-terminus has been replaced with an amino group(NH₂), i.e. the C-terminus has been amidated.

The abbreviations for the common individual amino acid residues are conventional and are based on the trivial name of the amino acid, e.g. pGlu is pyroglutamic
25 acid, Glu is glutamic acid, His is histidine, Trp is tryptophan, Ser is serine, Tyr is tyrosine, Gly is glycine, Leu is leucine, Nle is norleucine, Orn is ornithine, Arg is arginine, Har is homoarginine, Pro is proline, Sar is sarcosine, Phe is phenylalanine, Ala is
30 alanine, Val is valine, Nva is norvaline, Ile is isoleucine, Thr is threonine, Lys is lysine, Asp is aspartic acid, Asn is asparagine, Gln is glutamine, Cys is cysteine, and Met is methionine. Except for glycine, the amino acids which appear in the peptides of the
35 invention are of the L-configuration unless noted otherwise.

-3-

There are reasons for desiring to prevent ovulation in female mammals, and the administration of GnRH analogs that are antagonistic to the normal function of GnRH have been used to suppress or delay ovulation.

- 5 For this reason, analogs of GnRH containing D-isomers which are antagonistic to GnRH are being investigated for their potential use as a contraceptive or for regulating conception periods. GnRH antagonists may also be used for the treatment of precocious puberty and
- 10 endometriosis. Such antagonists have also been found useful to regulate the secretion of gonadotropins in male mammals and can be employed to arrest spermatogenesis, e.g. as male contraceptives, and for treatment of prostatic hypertrophy. More specifically, GnRH
- 15 antagonists can be used to treat steroid-dependent tumors, such as prostatic, brain and mammary tumors.

- It is desired to provide improved peptides which are strongly antagonistic to endogenous GnRH and which inhibit secretion of LH and the release of steroids by
- 20 the gonads of mammals. It is also desired to provide compounds which exhibit a longer duration of biological effectiveness *in vivo*. Further desires are to provide GnRH antagonists which have good solubility in aqueous media, such as saline buffers, and to provide such
- 25 peptides which exhibit substantial biological potency when administered orally.

SUMMARY OF THE INVENTION

- The present invention provides D-isomer-
- 30 containing peptides which inhibit the release of gonadotropins in mammals, including humans, and it also provides methods for inhibiting the release of steroids by the gonads of male and female mammals. These GnRH analogs are referred to as GnRH antagonists
- 35 because they are strongly antagonistic to GnRH and have an inhibitory effect on the reproduction processes of

-4-

mammalians. These analogs may be used to inhibit the production and/or secretion of gonadotropins and sex hormones under various circumstances, including precocious puberty, hormone dependent neoplasia, 5 dysmenorrhea, endometriosis and steroid-dependent tumors.

Generally, in accordance with the present invention, peptides have been synthesized which strongly inhibit the secretion of gonadotropins by the pituitary gland of mammals, including humans, and/or inhibit the 10 release of steroids by the gonads. These peptides are bicyclic analogs of GnRH wherein there are two covalent bonds, i.e., between the 4-position residue and the 10-position residue, and between the 5-position residue and the 8-position residue. Very generally, these GnRH 15 antagonists can be described as peptides having a decapeptide main chain, which peptide is effective to substantially reduce the secretion of LH by the pituitary, said peptide being an analog of mammalian GnRH wherein the N-terminus is preferably acylated, the C- 20 terminus is amidated, a side chain of the residue in the 4-position is connected by a covalent bond to the residue in the 10-position, and the side chain of the residue in the 5-position and the side chain of the residue in the 8-position are connected by amide linkages to the α - 25 carbon of an amino acid residue outside of said main chain.

More specifically, these peptides have β -(2-naphthyl)-D-alanine(hereinafter β -D-2NAL) in the 1-position or an equivalent residue in the 1-position as 30 well known in this art, such as D-Phe, D-Pro, L-Pro, D-Trp or dehydroPro, with dehydroPro being preferred if β -D-NAL is not present. The 1-position residue is preferably modified so that its alpha-amino group contains an acyl group, such as formyl(For), acetyl(Ac), 35 acrylyl(Acr), vinylacetyl(Vac) or benzoyl(Bz); acetyl is preferred; however, an equivalent acyl group can be

-5-

employed as well known in this art. A modified D-Phe residue is present in the 2-position which has specific modifications as well known in this art, principally substitutions in the benzene ring. Single substitutions for hydrogen in the ring are preferably made in the para- or 4-position, but might instead be in either the 2- or 3-position; such substitutions are selected from chloro, fluoro, bromo, methyl, methoxy and nitro, with chloro, fluoro and nitro being preferred. Dichloro substitutions may also be made in the 2,4 or 3,4 positions in the ring. The alpha-carbon atom may also be methylated, e.g. (C^αMe/4Cl)Phe.

The residue in the 3-position is a D-isomer such as unsubstituted or substituted D-Trp, D-3PAL, β -D-2NAL or β -D-1NAL. PAL and D-PAL represent the L- and D-isomers of pyridylalanine where the β -carbon of Ala is linked to the 2-, 3- or 4-position, preferably to the 3-position, on the pyridine ring. Although D-3PAL is the preferred residue in the 3-position, a known equivalent can instead be used.

The 4-position residue may be Abu or a dicarboxylic amino acid, preferably Asp, and the residue in the 10-position is, of course, complementary to the 4-position residue. Moreover, a dicarba bond between the residues in the 4- and 10-positions of a length slightly longer or shorter than that provided by a pair of Abu residues may also be employed.

The 5-position is occupied by Glu or Asp or homoglutamic acid (Hgl), preferably Glu, and the 8-position by Dbu or Orn or Dpr, preferably Dbu, with the side chains of these two residues being connected through a peptide linkage, with an additional α -amino acid being included in the linkage between the side chains of these two residues, as explained in detail hereinafter. Generally any α -amino acid may be used; however, those having a basic side chain, such as Arg, Har, His, 4gua-

-6-

Phe, gua-4methyl-Phe, 4NH₂-Phe(Aph), Lys, Orn and the like, or Phe may be preferred. In addition, there is a class of recently synthesized unnatural α-amino acids which include either a N'-cyano-N'-alkyl-(or aryl-)


5 guanidino moiety or an aminotriazole moiety that can also be used, which are referred to as UAA and are described hereinafter in more detail.

The peptide has D-Arg in the 6-position or an equivalent D-isomer chosen from those well known in this art. D-isomers of the aforementioned unnatural α-amino acids (D-UAAs) can also be present in the 6-position. The naturally occurring residue Leu is preferably in the 7-position; however, an equivalent such as Nle, NML, Phe, Nva, Met, Tyr, Trp or PAL can be present.

15 These GnRH antagonists have good duration of biological activity when tested in vivo. They are considered to have higher potency when administered orally compared to previously available GnRH antagonists. They have good solubility in saline solutions and other aqueous media. The peptides inhibit ovulation of female mammals when administered at low levels at proestrus and are also effective to cause resorption of fertilized eggs if administered shortly after conception. These peptides are also effective for the contraceptive treatment of male mammals and for the treatment of steroid-dependent and other tumors. Thus, they provide for improved methods of pharmaceutical treatment.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


30 More specifically, certain preferred bicyclic peptides of the present invention have the following formula:



-7-

wherein R_4 is Asp or Abu; R_5 is Glu, Hgl or Asp; R_6 is Dbu, Dpr or Orn; R_{10} is Dpr or Abu; and R_{11} is Gly, Ala, Sar, β -Ala, Leu, Har, Orn, Lys, Dbu, Dpr, Glu, Asp, NAL, (E)Phe, Arg, His, Tyr, Ser, Gln, Asn, Val, Nle, Nva, PAL, Ile, Trp, Cys or Cit; with E being defined hereinafter; provided however that when R_4 is Abu, R_{10} is Abu; and when R_4 is Asp, R_{10} is Dpr. Alternatively R_{11} can be UAA. Preferably when R_5 is Glu, R_6 is Dbu; when R_5 is Asp, R_6 is Orn; and when R_5 is Hgl, R_6 is Dpr.

10 Taking into account a number of the most common equivalent residues which may alternatively be employed, these GnRH antagonists may have the following general formula:



wherein X is hydrogen or an acyl group having 7 or less carbon atoms; R_1 is β -D-2NAL or dehydroPro; A is H, Cl, F, NO_2 , CH_3 , OCH_3 , $C^6Me/4Cl$, Cl_2 or Br; R_3 is β -D-2NAL, D-3PAL or D-Trp; R_4 is Asp or Abu; R_5 is Glu, Hgl or Asp; R_6 is β -D-NAL, (B)D-Trp, (A')D-Phe, (D)D-Har, D-Tyr, (C)D-His, D-PAL, (D)D-Arg, D-Leu, D-Ile, D-Val, D-Nle, D-Ala, D-Pro, D-Ser(OtBu), D-Nva or D-UAA; A' is A, NH_2 , $NHCH_3$ or gua; B is H, NO_2 , NH_2 , OCH_3 , F, Cl, Br, CH_3 , $N^{in}For$ or $N^{in}Ac$; C is H, imBzl or dinitrophenyl; D is H or di-lower alkyl; R_7 is Nle, Leu, NML, Phe, Met, Nva, Tyr, Trp or PAL; R_8 is Dbu, Dpr or Orn; R_{10} is Dpr or Abu; R_{11} is Gly, Ala, Sar, β -Ala, Leu, Har, Dbu, Dpr, Orn, Lys, Glu, Asp, NAL, (E)Phe, Arg, His, Tyr, Ser, PAL, Gln, Asn, Val, Nle, Nva, Ile, Trp, Cys, Cit or UAA; and E is gua, $guaCH_2$, NH_2 , H, Cl, F, Br, NO_2 , CH_3 , or OCH_3 ; provided however that when R_4 is Abu, R_{10} is Abu; and when R_4 is Asp, R_{10} is Dpr. Preferably when β -D-NAL is present in the 1-position, D-PAL, D-UAA or a hydrophilic D-amino acid residue, such as 4 NH_2 -D-Phe, 4-guanidino-D-Phe,

-8-


D-His, D-Arg or D-Har, is present in the 6-position. When dehydroPro is present in the 1-position, D-PAL, D-UAA, or a D-isomer of a lipophilic amino acid, such as D-Trp, D-Phe, For-D-Trp, NO₂-D-Trp, D-Leu, D-Ile, D-Nle, 5 D-Tyr, D-Val, D-Ala, D-Ser(OtBu), β -D-NAL or (imBzl)D-His, is preferably in the 6-position.

By dehydroPro is meant 3,4 dehydroproline, C₃H₇O₂N. By β -D-NAL is meant the D-isomer of alanine which is substituted by naphthyl on the β -carbon atom, 10 i.e., also termed 3-D-NAL. Preferably β -D-2NAL is employed wherein the attachment to naphthalene is at the 2-position on the ring structure; however, β -D-1NAL may also be used. PAL represents alanine which is substituted by pyridyl on the β -carbon atom; preferably 15 the linkage is to the 3-position on the pyridine ring. When substituted D-Trp is employed, single substitutions for hydrogen may be made in either the 5- or 6-position, which are selected from chloro, fluoro, bromo, methyl, amino, methoxy and nitro, with chloro, fluoro and nitro 20 being preferred. Alternatively, the indole nitrogen may be acylated, e.g. with formyl (N¹For- or 1For-) or with acetyl. N¹For-D-Trp and 6NO₂-D-Trp are the preferred substituted residues. When either D-Arg or D-Har is present in the 6-position, the guanidino side chain can 25 be di-substituted with lower alkyl(C₁ to C₄), preferably diethyl. By NML is meant N⁶CH₃-L-Leu, and by Cit is meant citrulline, having the formula CH₂(NHCONH₂)CH₂CH₂CH(NH₂)COOH. By Abu is meant 2-aminobutyric acid, and by Dbu is meant 30 2,4-diaminobutyric acid. By Dpr is meant 2,3-diaminopropionic acid. By 4-gua-D-Phe is meant a residue of D-Phe substituted in the para-position by a guanidino group; by (gua-4CH₃)D-Phe is meant a residue of D-Phe having a methyl group in the para-position which 35 is itself substituted with a guanidino group.

-9-

The unnatural L- or D-isomer α -amino acids (UAAs) have either (a) N'-cyano-N''-alkyl-(or aryl-)guanidino moieties formed on p-aminophenylalanine (Aph) or as a part of Har, Arg or a shortened version of Arg having 1 or 2 fewer CH₂-groups, wherein alkyl is preferably lower alkyl (C₁ to C₆) or cyclohexyl and aryl is preferably benzyl, histaminyl, naphthyl, tryptamino or pyridyl; or (b) an aminotriazole moiety (atz) on the distal amino group of Aph, Lys, Orn, Dbu or Dpr. These UAAs can be synthesized as disclosed in U.S. patent application Serial No. 545,239, filed June 27, 1990, the disclosure of which is incorporated herein by reference. The biopotency of GnRH antagonists incorporating such UAAs in the main chain was reported in Theobald et al., J. Medical Chemistry, 34, 2395-2402 (1991). Examples of some suitable UAAs which are modified homoarginine molecules include Har(mCN), Har(iCN), Har(bCN), Har(hCN), Har(chCN), Har(2mpCN), Har(eCN) and Har(bzCN) wherein m = methyl, e = ethyl, i = isopropyl, b = butyl, h = hexyl, ch = cyclohexyl, bz = benzyl and 2mp = 2-methylpyridyl. Once the UAA is synthesized, the α -amino group of the UAA can be protected with Boc, Fmoc or some other suitable group; the side chain should not normally require protection.

The following general formula defines a preferred subgenus of GnRH antagonists:




wherein X is hydrogen or an acyl group having 7 or less carbon atoms; R₁ is β -D-2NAL or dehydroPro; A is H, Cl, F, NO₂, CH₃, OCH₃, CMe/4Cl, Cl₂ or Br; R₃ is β -D-2NAL, D-3PAL or D-Trp; or R₅ is Glu, Hgl or Asp; R₆ is β -D-NAL, (B)D-Trp, (A')D-Phe, (D)D-Har, D-Tyr, (C)D-His, D-PAL, (D)D-Arg, D-Leu, D-Ile, D-Val, D-Nle, D-Ala, D-Pro,

-10-

D-Ser(OtBu), D-Nva or D-UAA; A' is A, NH₂, NHCH₃ or gua;
 B is H, NO₂, NH₂, OCH₃, F, Cl, Br, CH₃, NⁱⁿFor or NⁱⁿAc; C
 is H, imBzl or dinitrophenyl; D is H or di-lower alkyl;
 R₇ is Nle, Leu, NML, Phe, Met, Nva, Tyr, Trp or PAL; R₈
 5 is Dbu, Dpr or Orn; and R₁₁ is Gly, Ala, Sar, β-Ala, Leu,
 Har, NAL, (E)Phe, Arg, His, Tyr, Ser, Gln, Asn, Val,
 Nle, Nva, Ile, Trp, Cit or UAA; and E is gua, guaCH₂,
 NH₂, or H. When R₁ is β-D-NAL, then R₆ is preferably
 4-NH₂-D-Phe, D-Har, D-His, 4-gua-D-Phe, D-PAL or D-Arg.

10 Another preferred group of biologically active
 bicyclic peptides which have a covalent bond between the
 residues in the 4- and 10-positions and which have a
 cyclizing bond containing an α-amino acid residue
 between the side chains of the residues in the 5- and
 15 8-positions has the following formula:



20 wherein R₅ is Glu, Hgl or Asp; R₈ is Dbu, Dpr or Orn; and
 R₁₁ is Gly, Ala, Sar, β-Ala, Leu, Har, NAL, PAL, (E)Phe,
 Arg, Lys, Orn, Dbu, Dpr, His, Tyr, Ser, Gln, Asn, Val,
 Nle, Nva, Ile, Trp, Cys or Cit. E is as defined
 hereinbefore, and R₁₁ can alternatively be UAA.


25 Yet another preferred group of biologically
 active bicyclic peptides has the following formula:



30 wherein R₅ is Asp or Glu; R₈ is Dbu or Orn; and R₁₁ is
 Gly, Ala, Lys, Orn, Dbu, Dpr, Sar, β-Ala, Leu, Har, NAL,
 (E)Phe, Arg, His, Tyr, Ser, PAL, Gln, Asn, Val, Nle,
 Nva, Ile, Trp, Cys or Cit. E is as defined
 35 hereinbefore, and R₁₁ can alternatively be UAA.


-11-

In a particularly preferred group of bicyclic peptides, the formula is generally as set forth above except that R_5 is Asp or Glu and R_6 is Dbu or Orn. These bicyclic peptides have the following formula:




wherein R_5 is Asp or Glu; R_6 is Dbu or Orn; and R_{11} is a basic α -amino acid.

A presently most preferred group of bicyclic peptides has the following formula:



wherein R_5 is Asp or Glu; R_6 is Dbu or Orn; and R_{11} is (gua)Phe, (guaCH₂)Phe, Arg, Har or His, but alternatively R_{11} can be UAA.

20 It may be desirable to have a slightly shorter or longer cyclizing linkage between the two residues in the 4- and 10-positions than the dicarba linkage between Abu residues, and in such an instance, peptides may be synthesized having the formula:




wherein X is hydrogen or an acyl group having 7 or less carbon atoms; R_1 is β -D-2NAL or dehydroPro; A is H, Cl, F, NO₂, CH₃, OCH₃, CMe/4Cl, Cl₂ or Br; R_3 is β -D-2NAL, D-3PAL or D-Trp; R_5 is Glu, Hgl or Asp; R_6 is β -D-NAL, (B)D-Trp, (A')D-Phe, (D)D-Har, D-Tyr, (C)D-His, D-PAL, (D)D-Arg, D-Leu, D-Ile, D-Val, D-Nle, D-Ala, D-Pro, D-Ser(OtBu), D-Nva or D-UAA; A' is A, NH₂, NHCH₃ or gua; B is H, NO₂, NH₂, OCH₃, F, Cl, Br, CH₃, NⁱⁿFor or NⁱⁿAc; C is H, imBzl or dinitrophenyl; D is H or di-lower alkyl; R_7 is Nle,

-12-

Leu, NML, Phe, Met, Nva, Tyr, Trp or PAL; R_8 is Dbu, Dpr or Orn; R_{11} is Gly, Ala, Sar, β -Ala, Leu, Har, Orn, Lys, Glu, Asp, NAL, (E)Phe, Arg, His, Tyr, Ser, Gln, Asn, PAL, Val, Nle, Nva, Ile, Trp, Cit or UAA; E is gua,
 5 guaCH₂, NH₂, H, Cl, F, Br, NO₂, CH₃, or OCH₃, and n is an integer between 2 and 6 and preferably, n = 3 to 5. If the residues in positions 4 and 10 were both Abu, n would equal 4.

The peptides of the present invention can be
 10 synthesized by classical solution synthesis or by a solid phase technique using a chloromethylated resin, a hydroxymethylated resin, a methylbenzhydrylamine resin (MBHA), a benzhydrylamine (BHA) resin or any other
 15 suitable resin known in the art. The solid phase synthesis is conducted in a manner to stepwise add the amino acids in the chain in the manner set forth in detail in U.S. Patent No. 4,211,693. Side-chain
 20 protecting groups, as are well known in the art, are preferably added to the residues to be employed in the synthesis having particularly labile side chains and may optionally be added to others, such as Trp, before these amino acids are coupled to the chain being built upon the resin. Such synthesis provides the fully protected intermediate peptidoresin.

25 The "final" chemical intermediates made generally in accordance with the preferred procedure for producing bicyclic peptides having certain features of the invention are represented by Formula II:



X^1 is an alpha-amino protecting group of the type known to be useful in the art in the stepwise synthesis of polypeptides. Among the classes of alpha-amino
 35 protecting groups covered by X^1 are (1) acyl-type protecting groups, such as formyl(For), trifluoroacetyl,

-13-

- phthalyl, p-toluenesulfonyl (Tos), benzoyl (Bz), benzenesulfonyl, o-nitrophenylsulfenyl (Nps), tritylsulfenyl, o-nitrophenoxyacetyl, acrylyl (Acr), chloroacetyl, acetyl (Ac) and γ -chlorobutyryl;
- 5 (2) aromatic urethan-type protecting groups, e.g., benzyloxycarbonyl (Z), fluorenylmethyloxycarbonyl (Fmoc) and substituted benzyloxycarbonyl, such as p-chlorobenzyloxy-carbonyl (ClZ), p-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl and
- 10 p-methoxybenzyloxycarbonyl; (3) aliphatic urethan protecting groups, such as tertbutyloxycarbonyl (Boc), diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl and allyloxycarbonyl; (4) cycloalkyl urethan-type protecting groups, such as
- 15 cyclopentylloxycarbonyl, adamantylloxycarbonyl and cyclohexylloxycarbonyl; (5) thiourethan-type protecting groups, such as phenylthiocarbonyl; (6) alkyl-type protecting groups, such as allyl (Aly), triphenylmethyl (trityl) and benzyl (Bzl);
- 20 (7) trialkylsilane groups, such as trimethylsilane. The preferred alpha-amino protecting group is Boc, except for the protection of the α -amino group of R_1 .
- X^2 is hydrogen or a suitable protecting group for the indole nitrogen of Trp, such as Bz.
- 25 X^3 is a suitable, preferably hydrazine-labile, protecting group for a carboxyl side chain, such as OChx (cyclohexyl ester) or OBzl (benzyl ester); or is a direct bond between the residues R_i and R_{10} . X^{3a} is an acid-labile protecting group for an amino group, e.g.
- 30 2Cl-Z or t-amylloxycarbonyl, or is a direct bond between residues R_i and R_{10} .
- X^4 is hydrogen or a protecting group for the phenolic hydroxyl group of Tyr selected from the group consisting of tetrahydropyranyl, tert-butyl, trityl, benzyl, Z, 2-bromobenzyloxycarbonyl (2BrZ) and
- 35 2,6-dichlorobenzyl (DCB). 2BrZ is preferred.

-14-

X^5 is a protecting group for a side chain guanidino group in Arg or the like, or for the imidazole group of His, such as nitro, Tos, trityl, adamantyloxycarbonyl, Z and 2,4-dinitrophenyl (DNP), or X^5 may be hydrogen, which means there is no protection on the labile side chain group. Tos is generally preferred.

X^6 is a base-labile protecting group for a carboxyl group, preferably fluorenylmethyl ester (OFm).

X^7 is hydrogen or a protecting group for Met, such as oxygen.

X^8 is a base-labile protecting group for an amino group, preferably Fmoc. Neither X^6 nor X^8 appears in the "final" intermediate.

X^9 is hydrogen or a suitable side chain-protecting group as described above or as generally known in this art.

X^{10} may be $O-CH_2$ -[resin support], $-NH$ -[resin support], OH, ester or NH_2 .

The criterion for selecting side-chain protecting groups for X^2 - X^9 is that the protecting group should be stable to the reagent under the reaction conditions selected for removing the alpha-amino protecting group (e.g. Boc) at each step of the synthesis. Generally, the protecting group should not be split off under coupling conditions but will be removed upon completion of the synthesis of the desired amino acid sequence under reaction conditions that will not alter the peptide chain; however, certain of the protecting groups, e.g. X^6 and X^8 , are chosen to be removable without the removal of other of the protecting groups in some syntheses.

When the X^{10} group is $-O-CH_2$ -[resin support], the ester moiety of one of the many functional groups of a polystyrene resin support is being represented. When the X^{10} group is $-NH$ -[resin support], an amide bond connects R_{10} to a BHA resin or to a MBHA resin.

-15-

When the N-terminus is acylated, as is preferably the case, a reaction is preferably carried out with the intermediate peptide on the resin (after removing the Boc-protection from the N-terminal alpha-amino group while the labile side chains remain protected), e.g. by reacting with acetic acid in the presence of dicyclohexyl carbodiimide (DCC) or preferably with acetic anhydride, or by another suitable reaction as known in the art, to attach an acetyl group.

The bicyclic peptides can be made using various protocols as generally known in this art. For example, U.S. Patent No. 5,064,939, issued November 12, 1991, the disclosure of which is incorporated herein by reference, discloses a variety of suitable protocols depending upon the character of the bond between the residues in the 4- and 10-positions. Likewise, the incorporation of the alpha-amino acid in the linkage between the residues in the 5- and 8-positions can be accomplished in several different ways, for example, by using an appropriately blocked dipeptide when adding the residue that will occupy either the 8- or the 5-position in the step-by-step peptide building sequence; however, to avail oneself of commercially available starting materials, it may be advantageous to add this "nonbackbone" alpha-amino acid to either the residue in the 8-position or the residue in the 5-position after it has been incorporated into the main chain of the peptide being synthesized.

Very generally, the preferred bicyclic peptides are made by carrying out solid-phase synthesis on a suitable resin and performing at least one cyclizing step while the peptide intermediate is a part of the peptidoresin, and preferably before the entire peptide has been synthesized. After this first cyclization is effected, the synthesis of the decapeptide main chain is completed. At such time, if the bond between the 4- and

-16-

10-position residues is of the dicarba type (as discussed hereinafter), the second cyclization will have been completed. If the bond being established between the 4- and 10-position residues is an amido bond, cyclization may be carried out on the resin, but it is preferably effected following cleavage. Accordingly, the protected peptide would then be suitably cleaved from the resin. For example, if a hydroxymethylated resin or a chloromethylated resin support is used, cleavage by ammonolysis is used, as is well known in the art, to yield the fully protected, C-terminally amidated intermediate; alternatively, if a benzhydrylamine resin is used, treatment with hydrofluoric acid (HF) causes deprotection of side chains as well as cleavage of the peptide from the resin as a C-terminal amide.

As indicated above, it is generally preferred to carry out the final cyclizing step to form the bond between the position 4- and 10-residues following the cleavage from the resin. When the cyclization is via creating an amide bond between a side-chain carboxyl group of the 4-position residue and a side-chain amino group of the 10-position residue (which is the presently preferred bond), it is preferable to synthesize the protected peptide on an MBHA or BHA resin and to derivatize a cyclohexyl or benzyl ester protecting group of the carboxyl acid side chain to form a hydrazide while the peptide is still attached to the resin. This can be accomplished by using OChx or OBzl as a protecting group for the carboxyl side-chain of the residue to be involved in the amide-bond bridge. Following this selective hydrazide activation, deprotection of the remainder of the side-chain protecting groups and cleavage from the resin are effected. Then reaction to accomplish cyclization is carried out by treating with isoamyl nitrite and a strong acid, such as HCl, to generate the azide which in turn

-17-

reacts with the free amino group on the side chain of the 4-position residue to ultimately generate the amide bond.

5 Analogues of GnRH which include the equivalent of modified cysteine residues in the 4- and 10-positions wherein the disulfide linkage has been replaced by -CH₂-linkage are referred to as dicarba. In general, syntheses of cyclic peptides of this particular type are exemplified by the teachings of the following U.S. Patents Nos. 4,115,554 (September 19, 1978); 4,133,805 (January 9, 1979); 4,140,767 (February 20, 1979); 4,161,521 (July 17, 1979); 4,191,754 (March 4, 1980); 4,238,481 (December 9, 1980); 4,244,947 (January 13, 1981); and 4,261,885 (April 14, 1981).

15 As a comparison of the ultimate peptide to one having a Cys-Cys disulfide bond, the location which would be occupied by a Cys residue instead contains a residue of alpha-amino butyric acid (Abu). When preparing peptides having such a dicarba linkage or a longer or shorter chain dicarba-type linkage, the procedure set forth in either U.S. Patent No. 4,161,521 or U.S. Patent No. 4,703,106 is preferably employed (the disclosures of which patents are incorporated herein by reference). In the peptide intermediate so synthesized, 25 X³ and X^{3a} represent a direct bond via one side chain to the other residue.

 It has been found to be particularly advantageous to carry out the solid-phase synthesis of certain of these preferred bicyclic GnRH antagonist peptides having an amide linkage between the 4- and 10-position residues using an MBHA resin or the equivalent. After attaching the first 5 residues of the main chain, i.e. the residues which will occupy positions 6-10 of the GnRH antagonists, the "nonbackbone" residue is 35 added. The side chain amino group of the 10-position residue is appropriately blocked with benzyloxycarbonyl

-18-

(Z) is an equivalent protecting group that will not be removed under basic conditions. Boc or an equivalent is used as the alpha-amino protecting group for all of the amino acids in the main chain, and the side chain amino group of the 8-position residue is protected with Fmoc. Following the creation of the pentapeptide, the Fmoc protection on the side chain amino group of this residue in the main chain of the pentapeptide is removed using piperidine, and the nonbackbone residue (which has its alpha-amino group protected by Fmoc and has any labile side chain appropriately protected) is coupled to the side chain of the 8-position residue using standard coupling conditions.

Following this coupling, the Boc-protecting group is removed from the 6-position residue, and the 5-position residue is added, having its carboxyl side chain protected with OFm. Following this coupling step, the Fmoc and OFm side chain protecting groups are removed by treatment with piperidine, and then cyclicization is effected by treatment with BOP [Benzotriazolyl-N-oxytris(dimethylamino)-phosphonium hexafluorophosphate] and diisopropylethylamine. Following cyclicization, the Boc-protecting group is removed from the N-terminus of the hexapeptide main chain, and the synthesis of the decapeptide main chain is completed using OBzl or OChx as the side chain carboxyl protecting group for the 4-position residue. Thereafter, following completion of the decapeptide main chain, and then removal of the Boc protecting group at the N-terminus and acylation thereof, the peptidoresin is treated for about 60 hours at room temperature with hydrazine in order to form the hydrazide on the side chain of the 4-position residue. Thereafter, the peptidoresin is treated with HF to remove the remaining protecting groups and cleave the peptide from the resin. Finally, treatment with HCl and isoamyl nitrate at a

-19-

temperature below 0°C, followed by the addition of N,N-diisopropylethylamine is used to effect an azide coupling reaction, which results in creation of an amide bond between the side chains of the residues in the 4- and 10-positions.

Thus, for example, the invention also provides a method for making certain preferred bicyclic peptides or nontoxic salts thereof, which peptides have the Formula I:

10
$$X-R_1-(A)D-Phe-R_3-\overbrace{R_4-R_5-R_6-R_7-R_8}^{R_{11}}-Pro-R_{10}-NH_2$$
, wherein X is hydrogen or an acyl group having 7 or less carbon atoms; R_1 is β -D-2NAL or dehydroPro; A is H, Cl, F, NO₂, CH₃, OCH₃, CMe/4Cl, Cl₂ or Br; R_3 is β -D-2NAL, D-3PAL or
 15 D-Trp; R_4 is Asp or Abu; R_5 is Glu, Hgl or Asp; R_6 is β -D-NAL, (B)D-Trp, (A')D-Phe, (D)D-Har, D-Tyr, (C)D-His, D-PAL, (D)D-Arg, D-Leu, D-Ile, D-Val, D-Nle, D-Ala, D-Pro, D-Ser(OtBu), D-Nva or D-UAA; A' is A, NH₂, NHCH₃ or gua; B is H, NO₂, NH₂, OCH₃, F, Cl, Br, CH₃, NⁱⁿFor or
 20 NⁱⁿAc; C is H, imBzl or dinitrophenyl; D is H or di-lower alkyl; R_7 is Nle, Leu, NML, Phe, Met, Nva, Tyr, Trp or PAL; R_8 is Dbu, Dpr or Orn; R_{10} is Dpr or Abu; R_{11} is Gly, Ala, Sar, β -Ala, Leu, Har, Orn, Lys, Dbu, Dpr, PAL, Glu, Asp, NAL, (E)Phe, Arg, His, Tyr, Ser, Gln, Asn, Val,
 25 Nle, Nva, Ile, Trp, Cys, Cit or UAA; and E is gua, guaCH₂, NH₂, H, Cl, F, Br, NO₂, CH₃, or OCH₃; provided however that when R_4 is Abu, R_{10} is Abu; and when R_4 is Asp, R_{10} is Dpr; which method comprises (a) forming a first intermediate compound having the formula:
 30 $X^1-R_6(X^4 \text{ or } X^5)-R_7(X^2 \text{ or } X^4 \text{ or } X^7)-R_8(X^8)-Pro-R_{10}(X^{3a})-X^{10}$;

-20-

(b) removing (X^8) and coupling (X^8) R_1 (X^9) to the side chain of R_3 ; (c) coupling R_5 to R_6 to create a second intermediate having the formula: X^1 - R_5 (X^6)- R_4 (X^4 or X^3)- R_7 (X^2 or X^4 or X^7)- R_8 -Pro- R_{10} (X^{10})- X^{10} ;

$$5 \quad X^8 - R_1(X^9) \quad \text{—}$$

(d) removing (X^6) from R_3 and X^8 from R_1 , and creating a cyclizing amide bond; (e) then forming a third intermediate compound having the Formula II:

$$X^1-R_1-(A)D-Phe-R_3(X^2)-R_4(X^3)-R_5-R_6(X^4 \text{ or } X^5)-R_7(X^2 \text{ or } X^4)$$

10 $\boxed{\text{---} R_1(X^9) \text{---}}$

or X^7)- R_8 -Pro- R_{10} (X^{3a})- X^{10} wherein X^1 is hydrogen or an alpha-amino protecting group; X^2 is hydrogen or a protecting group for an indole nitrogen; X^3 and X^{3a} are a direct bond between R_4 and R_{10} or acid-labile protecting groups for carboxyl or amino side chains; X^4 is hydrogen or a protecting group for a phenolic hydroxyl group of Tyr; X^5 is hydrogen or a protecting group for a guanidino or imidazole side chain; X^6 is a base-labile protecting group for a carboxyl group; X^7 is a protecting group for Met; X^8 is a base-labile protecting group for an amino moiety; X^9 is hydrogen or an appropriate side chain protecting group; and X^{10} is selected from the group consisting of $O-CH_2$ -(resin support), $-NH$ -(resin support), esters, and amides; (f) converting X^3 to a hydrazide;

25 (g) splitting off any remaining protecting groups and
cleaving from said resin support; (h) creating a
cyclizing bond between R_4 and R_{10} and, if desired, (i)
converting a resulting peptide into a nontoxic salt
thereof. The so-called "final" intermediate for certain
30 preferred bicyclic peptides is that having the formula:
 $X^1-R_1-(A)D-Phe-R_4(X^2)-R_4(X^3)-X^5-R_4(X^4 \text{ or } X^3)-$

$$R_7(X^2 \text{ or } X^4 \text{ or } X^7) - X^8 - \text{Pro-}R_{10}(X^{3e}) - X^{10}.$$

Purification of the peptide may be effected by
35 ion exchange chromatography on a CMC column, followed by
partition chromatography using the elution system:

-21-

n-butanol;0.1N acetic acid (1:1 volume ratio) on a column packed with Sephadex G-25. Purification is preferably carried out by using RP-HPLC as known in this art, and as set forth specifically in J. Rivier, et al.

5 J. Chromatography, 288 (1984) 303-328.

The peptides of the invention are considered to be effective to prevent ovulation in female rats when administered at about noon on the day of proestrus, at levels of less than 100 micrograms per kilogram of body weight. For prolonged suppression of ovulation, it may be desirable to use dosage levels in the range of from about 0.1 to about 2.5 milligrams per kilogram of body weight per day. These antagonists are also effective to arrest spermatogenesis when administered to male mammals on a regular basis and can thus be used as
10 contraceptives. Since these compounds will reduce testosterone levels (an undesired consequence in the normal, sexually active male), it may be reasonable to administer replacement dosages of testosterone along with the GnRH antagonist. These antagonists can also be used to regulate the production of gonadotropins and sex
15 steroids for other purposes as indicated hereinbefore.

These improved bicyclic GnRH antagonists are generally characterized by a substantial ability to suppress the secretion of LH in a standard rat pituitary cell assay when administered together with a concentration of 3 nanomolar GnRH, the details of which assay are set forth in Rivier and Vale, Life Sciences,
25 23, 869-876 (1978). By substantial ability is meant that, at a concentration of GnRH antagonist to GnRH of about 2/1 or less, the amount of LH secreted is reduced by 50% (IDR₅₀). Moreover, when tested in vivo in the standard rat anti-ovulation assay (Corbin et al. Endocrine Res. Commun., 2, 1 (1975)), these GnRH
30 antagonists show complete blockage of ovulation when

-22-

administered at about 200 μ g or less per kilogram of body weight.

The following examples set forth preferred methods for synthesizing GnRH antagonists using the solid-phase technique. These examples illustrate the best mode presently known to the inventors for making these peptides; however, as indicated hereinbefore, alternative methods of syntheses are available and can be employed, including classical solution-phase synthesis. Accordingly, these examples should be considered as illustrative to be taken into consideration in conjunction with the remainder of this specification and not as limiting.

15

EXAMPLE I

Bicyclic peptides as set forth in TABLE I having the formula:



are prepared by the solid-phase procedure referred to above.

-23-

TABLE I

	No.	R ₅	R ₆	R ₈	R ₁₁
5	1	Glu	D-Arg	Dbu	Arg
	2	"	"	"	Gly
	3	Asp	"	"	"
	4	"	"	"	β -Ala
	5	Glu	"	"	Sar
10	6	"	"	Dpr	Phe
	7	"	"	Dbu	"
	8	"	"	Orn	"
	9	Asp	"	Dbu	"
	10	"	"	Orn	"
15	11	Glu	"	Dbu	β -2NAL
	12	"	"	"	His
	13	"	β -D-2NAL	"	Arg
	14	"	D-Arg	"	(4Cl)Phe
	15	Asp	D-Trp	Dpr	Har
20	16	Glu	D-3PAL	Dbu	(gua)Phe
	17	"	D-Arg	"	Aph(atz)

For purposes of an example, a representative solid phase synthesis of Peptide No. 1 above, which is referred to as (Cyclo 4-10,5,5'-8)[Ac- β -D-2NAL¹, (4Cl)D-Phe², D-3PAL³, Asp⁴, Glu⁵(Arg), D-Arg⁶, Dbu⁸, Dpr¹⁰]-GnRH is set forth hereinafter. This peptide has the following formula: Ac- β -D-2NAL-(4Cl)D-Phe-

$$\text{D-3PAL-Asp-Glu-D-Arg-Leu-}\overbrace{\text{Dpr-NH}_2}^{\text{Arg}}\text{.}$$
 The other peptides in the table are similarly synthesized and purified.

Four grams of MBHA resin are used, and Boc-protected Dpr is coupled to the resin over about a 3-hour period in mixture of dimethylformamide (DMF) and

-24-

dichloromethane (DCM) in about equal parts using a 3-fold excess of Boc derivative and DCC as an activating reagent. The Dpr residue attaches to the MBHA resin by an amide bond.

- 5 Following the coupling of each amino acid residue, washing, deblocking and coupling of the next amino acid residue is carried out in accordance with the following schedule, using an automated machine and the amounts stated, when beginning with about 4-5 grams of
10 resin:

	STEP	REAGENTS AND OPERATIONS	MIX TIMES MIN.
	1	DCM wash-80 ml. (2 times)	3
	2	Methanol(MeOH) wash-30 ml. (2 times)	3
	3	DCM wash-80 ml. (3 times)	3
15	4	50 percent TFA plus 5 percent 1,2-ethanedithiol in DCM-70 ml. (2 times)	10
	5	Isopropyl alcohol + 1% ethanedithiol wash-80 ml. (2 times)	3
	6	TEA 12.5 percent in DCM-70 ml.	5
20	7	MeOH wash-40 ml.	2
	8	TEA 12.5 percent in DCM-70 ml.	5
	9	DCM wash-80 ml. (3 times)	3
	10	Boc-amino acid (10 mmoles) in 30 ml. of either DMF:DCM or DMF alone, depending upon the solubility of the particular protected amino acid, plus DCC (10 mmoles) in DCM	30-300
25	11	MeOH wash-40 ml. (2 times)	3
	12	TEA 12.5 percent in DCM-70 ml.	3
30	13	MeOH wash-30 ml. (2 times)	3
	14	DCM wash-80 ml. (2 times)	3

The above schedule is used for coupling each of the amino acids of the peptide after the first amino acid
35 has been attached. N^{Boc} protection is used for each of

-25-

the remaining amino acids throughout the synthesis, except for Arg which is protected with Fmoc. The side chain of Arg or D-Arg is protected with Tos. Fmoc is used as a side-chain protecting group for the amino group of Dbu; whereas Z is used to protect the side-chain amino group of Dpr. The carboxyl group of the side chain of Glu is protected with OFm, whereas the carboxyl group of the side chain of Asp is protected with OChx. N^εBoc-β-D-2NAL is introduced as the final amino acid and is prepared by a method known in the art, e.g. as described in detail in U.S. Patent No. 4,234,571, issued November 18, 1980. All the amino acids are coupled using a DMF:DCM mixture, except for Boc-D-Arg(Tos), which is coupled in DMF.

Following the assembly of a pentapeptide main chain intermediate on the MBHA resin, having the formula: Boc-D-Arg(Tos)-Leu-Dbu(Fmoc)-Pro-Dpr(Z)-MBHA resin support, the deprotection of the Dbu side chain is carried out by treatment with about 50 ml of 20 volume % piperidine in DMF for 15 minutes at about 22°C., followed by washing. Following the removal of the side-chain protecting group on Dbu, N^εFmoc-Arg(Tos) is added under standard coupling conditions so that the alpha-carboxyl group forms an amide bond to the side chain amino group on the Dbu residue.

Following washing in the usual manner, the synthesis of the main chain of the peptide is continued by the addition of N^εBoc-Glu(OFm) under standard coupling conditions. Following washing, the peptidoresin is treated with about 50 milliliters of 20 volume percent piperidine in DMF for about 15 minutes at room temperature, followed by washing, to remove the Fmoc protecting group on the alpha-amino group of Arg and the OFm protecting group on the side chain of Glu. Then the peptidoresin is suspended with about 5 meq. (2.2 gm) of

-26-

BOP [Benzotriazolyl-N-oxytris(dimethylamino)-phosphonium hexafluorophosphate] and 15 meq. of diisopropylethylamine and stirred for about 4 hours at 65°C and then overnight at room temperature to effect cyclization between the side chain of Glu and the α -amino group of Arg. The peptidoresin is filtered and then washed with DMF, MeOH, DCM and MeOH. Thereafter, the Boc-protecting group is removed from the N-terminus of cyclic peptide, and the synthesis of the remainder of the decapeptide main chain is completed to produce the further intermediate:

Boc- β -D-2NAL-(4Cl) D-Phe-D-3PAL-Asp(OChx)-Glu-D-Arg(Tos)-
└─────────────────── Arg(Tos) ─────────────────┘
 Leu-Dbu-Pro-Dpr(Z)-MBHA resin support.

15 After deblocking the alpha-amino group at the
N-terminus using trifluoroacetic acid (TFA), acetylation
is achieved using a large excess of acetic anhydride in
dichloromethane. This resultant product is sometimes
referred to as the "final" intermediate. Thereafter,
20 about 4 g. of protected-peptidyl resin is suspended at
room temperature in 40 ml of DMF, and 1 ml. of anhydrous
hydrazine (30-40x excess) is added to it under continuous
stirring. Nitrogen is bubbled through the reaction
mixture, and continuous stirring is effected in a closed
25 vial for about 3 days. The resin is filtered, washed 3
times with DMF, twice with MeOH, and 3 times with DCM,
and then finally dried.

About 4 g. of the protected peptide-hydrazide-resin is treated with 100-150 ml of distilled HF, in the presence of 10 ml of anisole as a scavenger, at 0°C. for about 40 minutes to remove the remaining protecting groups and cleave the peptide from the resin. HF is removed under high vacuum, and the peptide is precipitated with anhydrous ethyl ether. The solid material is collected, dissolved in 50 ml $\text{CH}_3\text{CN}:\text{H}_2\text{O}$ (1:1)

-27-

and lyophilized. It is then purified using RP-HPLC prior to final cyclizing.

1000 mg of the peptide-hydrazide is dissolved in 15 ml of DMF and cooled to about -25°C., and N₂ gas is bubbled therethrough. 0.56 ml (about 2.25 mmol) of 4N HCl in dioxane is added, and finally 105 µl (about 0.78 mmol) of isoamyl nitrite is added over ten minutes. Stirring at -25°C. is continued for 3 hours. The azide-solution is diluted with 1000 ml of precooled DMF (-25°C.); N,N-diisopropylethylamine is added in suitable portions to give a final pH of 7.8. The pH is checked and readjusted several times.

The solution is stored at 4°C. for 3 days, then evaporated to dryness in high vacuum. The residue is triturated in the presence of ethyl ether, and the solid is collected and dried in vacuum.

Final purification of the peptide is then effected by analytical and preparative RP-HPLC separations. The analytical HPLC preferably uses a TEAP (triethylammonium phosphate) buffer system, and the preparative HPLC uses a TEAP buffer system followed by a TFA buffer system, as described in detail in the J. Chromatography article.

The peptide is judged to be homogeneous using thin layer chromatography and several different solvent systems, as well as by reversed-phase high performance liquid chromatography using an aqueous triethylammonium phosphate solution plus acetonitrile. Amino acid analysis of the resultant, purified peptide is consistent with the formula for the prepared structure, showing substantially integer-values as expected for each amino acid. The optical rotation of Peptide No. 1 is measured on a photoelectric polarimeter as

$$[\alpha]_D^{22} = -42 \pm 1 (c=0.72, 50\% \text{ acetic acid}).$$

-28-

The peptides from Table I are assayed in vivo and are also tested in vitro using dissociated rat pituitary cells maintained in culture for 4 days prior to the assay. The levels of LH mediated in response to the application of peptides is assayed by specific radioimmunoassay for rat LH, as set forth in detail in Life Sciences, supra. Control dishes of cells only receive a measure which is 3 nanomolar in GnRH; experimental dishes receive a measure 3 nanomolar in GnRH plus a measure having either the present standard antagonist for comparison purposes, i.e. [Ac-dehydroPro¹, (4F)D-Phe², D-Trp^{3,6}]-GnRH, or the test peptide, in concentrations ranging from 0.01 to 10 nanomolar. The amount of LH secreted in the samples treated only with GnRH is compared with that secreted by the samples treated with the antagonist peptide plus GnRH. The ability of the test peptide to reduce the amount of LH released by 3 nanomolar GnRH is compared to that of the present standard peptide. All of the peptides exhibit substantial biological potency for inhibiting the release of LH in such in vitro assays.

In vivo testing determines effectiveness to prevent ovulation in female rats. In this test, a specified number of mature female Sprague-Dawley rats, e.g. usually five to ten, each having a body weight from about 225 to 250 grams, is injected with a specified microgram dosage of peptide in either saline or bacteriostatic water at about noon on the day of proestrus. Proestrus is the afternoon of ovulation. A separate female rat group is used as a control to which the peptide is not administered. Each of the control female rats ovulates on the evening of proestrus, and the number of the treated rats which ovulate is recorded. The results are set forth in the following Table A, wherein the dosages stated are in micrograms per rat.

-29-

TABLE A

	<u>Peptide No.</u>	<u>Dosage</u>	<u>Rats Ovulating</u>	<u>Dosage</u>	<u>Rats Ovulating</u>
5	1.	2.5	0/4	1.0	2/11
	2.	25	0/3	10	1/6
		5	2/8	2.5	6/8
	3.	25	0/5	10	4/6
	4.	10	4/5	5	7/10
				2.5	9/14
	5.	10	4/9		
10	6.	10	6/8		
	7.	10	0/9	5	1/8
		2.5	3/10	1.0	4/7
	8.	25	0/8	10	5/5
	9.	10	0/4		
	10.	5	0/4	2.5	6/6
15	11.	10	0/4	5	1/7
	12.	2.5	3/8	1.0	4/4
	13.	10	5/6	2.5	7/7
	14.	5	0/6	2.5	3/4

20 Peptide No. 1 is considered to be significantly effective to prevent ovulation of female rats at a very low dosage. It is considered to be totally effective at a dose of about 50 micrograms per Kg of body weight, and it should

25 likely be effective at about 5 μ g/Kg. All of the peptides listed in Table I are considered effective to block GnRH-induced LH secretion and to prevent the ovulation of female mammals at dosages of about 200 μ g/Kg of body weight or less.

-30-

EXAMPLE II

Peptides as indicated in TABLE II having the formula:

5 Ac-dehydroPro-(A)D-Phe-D-3PAL-R₄-R₅-D-Trp-Leu-R₈-Pro-R₁₀-NH₂ are prepared by the solid-phase procedure referred to above.

TABLE II

10

	A	R ₄	R ₅	R ₈	R ₁₀	R ₁₁
18	4F	Asp	Asp	Orn	Dpr	Gly
19	"	"	"	"	"	Phe
15 20	"	Abu	Hgl	Dpr	Abu	His
21	"	"	"	"	"	Arg
22	"	Asp	"	"	Dpr	Asn
23	4Br	"	Asp	Orn	"	Met
24	"	Abu	"	"	Abu	Nle
20 25	H	"	"	"	"	Leu
26	4NO ₂	"	Glu	Dbu	"	Nva
27	"	Asp	"	"	Dpr	Tyr
28	2,4Cl ₂	"	"	"	"	Trp
29	"	"	Hgl	Dpr	"	3PAL
25 30	C ⁶ Me/4Cl	Abu	"	"	Abu	2NAL
31	3,4Cl ₂	"	"	"	Abu	Val

The peptides listed in Table II are considered effective to block GnRH-induced LH secretion in vitro at reasonable concentrations. All of the peptides are considered to be effective to prevent ovulation of female mammals at low dosages.

-31-

EXAMPLE III

Peptides as indicated in TABLE III having the formula:

5 $X-\beta-D-2NAL-(4Cl)D-Phe-D-3PAL-R_4-\overbrace{Glu-R_6-NML-Dbu-Pro}^{R_{11}}-R_{10}-NH_2$ are prepared by the solid-phase procedure referred to above.

TABLE III

	X	R ₄	R ₆	R ₁₀	R ₁₁	
10						
	32	Ac	Abu	D-Arg(bCN)	Abu	Lys
	33	Acr	Abu	D-Aph(iCN)	Abu	Orn
	34	For	Asp	D-Aph(atz)	Dpr	Phe
	35	Bz	"	D-Arg(iCN)	"	Sar
15	36	Ac	"	D-His	"	Ser
	37	Vac	"	(Et ₂)D-Har	"	Gln
	38	Acr	"	D-Lys(atz)	"	Ile
	39	Ac	Abu	D-Aph(bzCN)	Abu	Val
	40	Acr	"	D-Dbu(atz)	"	Glu
20	41	Ac	"	D-Arg(bzCN)	"	Gly
	42	"	"	D-2PAL	"	Nle
	43	Vac	"	D-Aph(bCN)	"	Cit
	44	Bz	Asp	D-Har	Dpr	Leu

25

Peptides such as Nos. 32 and 33 are synthesized by employing the general teaching of U.S. Patent No. 4,161,521.


Each of the peptides listed in Table III is considered effective to block GnRH-induced LH secretion in vitro at a reasonable concentration. All of the peptides are considered to be effective to prevent ovulation of female mammals at low dosages.

30

-32-

EXAMPLE IV

Peptides as indicated in TABLE IV having the formula:



5 Dpr-NH_2 are prepared by the solid-phase procedure referred to above.

TABLE IV

		R_1	R_7	R_{11}
10	45	β -D-2NAL	Nle	Arg(bCN)
	46	(1Ac)D-Trp	Met	Har(iCN)
	47	(6Br)D-Trp	Tyr	Har(mCN)
	48	(5F)D-Trp	Nle	(4F)Phe
15	49	(6NO ₂)D-Trp	Met	Aph(iCN)
	50	(5Cl)D-Trp	Tyr	(gua4CH ₂)Phe
	51	(4Cl)D-Phe	Phe	Aph(atz)
	52	(4F)D-Phe	4F-D-Phe	Lys(atz)
	53	(2,4Cl ₂)D-Phe	NML	His
20	54	dehydroPro	Nle	Dpr(atz)
	55	β -D-1NAL	Trp	Har
	56	(6OCH ₃)D-Trp	Leu	Dbu(atz)
	57	(5NH ₂)D-Trp	Nva	Arg(eCN)
	58	(4NO ₂)D-Phe	NML	Lys
25	59	Pro	Tyr	Har(bzCN)

When peptides such as Nos. 58 and 59 are synthesized, the amino side chain of the R_{11} residue, e.g., Lys, is blocked with a protecting group, such as alloc, which is not removed during HF cleavage from the resin, but which is instead removed later following completion of the second cyclizing bond.

All peptides listed in Table IV are considered effective to block GnRH-induced LH secretion in vitro at a reasonable concentration. All of the

-33-

peptides are considered to be effective to prevent ovulation of female mammals at low dosages.

EXAMPLE V

Peptides as indicated in TABLE V having the

5 formula: $\text{Ac}-\beta\text{-D-2NAL}-(4\text{F})\text{D-Phe}-\text{R}_3-\text{Asp}-\text{Glu}-\text{R}_6-\text{Tyr}-\text{Dbu}-\text{Pro-Dpr-NH}_2$ are prepared by the solid-phase procedure referred to above.

TABLE V

10

	R_3	R_6	R_{11}
	60 (6NO ₂) D-Trp	D-Arg(mCN)	(gua4CH ₂) Phe
15	61 (5CH ₃) D-Trp	(DNP) D-His	Lys(atz)
	62 (5OCH ₃) D-Trp	(4gua) D-Phe	(4gua) Phe
	63 β -D-2NAL	(6NO ₂) D-Trp	Arg(bzCN)
	64 β -D-1NAL	D-Aph(atz)	Arg(iCN)
	65 (1For) D-Trp	(Et ₂) D-Arg	Har(chCN)
20	66 (5F) D-Trp	(5NH ₂) D-Trp	Cit
	67 (5Cl) D-Trp	D-Aph(atz)	Aph(bCN)
	68 D-2PAL	D-Nle	(4NH ₂) Phe
	69 (1Ac) D-Trp	(4F) D-Phe	Aph(bzCN)
	70 D-3PAL	D-Aph(eCN)	(4CH ₃) Phe
25	71 "	(4NHCH ₃) D-Phe	Aph(atz)
	72 "	(Ipr ₂) D-Arg	Har(2mpCN)
	73 (5NH ₂) D-Trp	D-Lys(atz)	Lys(atz)
	74 (6Br) D-Trp	(1For) D-Trp	Arg(bCN)
	75 D-4PAL	D-Aph(iCN)	Aph(iCN)

30

Each of the peptides specified in Table V is considered effective to block GnRH-induced LH secretion in vitro at a reasonable concentration. All of the peptides are considered to be effective to prevent

35 ovulation of female mammals at low dosages.

-34-

EXAMPLE VI

Peptides as indicated in TABLE VI having the

formula: $X-R_1-(4F)D-Phe-D-Trp-\overbrace{R_4}^{R_1}-Glu-R_6-Leu-Dbu-$

5 $Pro-R_{10}-NH_2$ are prepared by the solid-phase procedure referred to above.

10

TABLE VI

		X	R ₁	R ₄	R ₆	R ₁₀	R ₁₁
	76	Acr	dehydroPro	Asp	D-Lys(atz)	Dpr	Ala
	77	Ac	"	"	D-Aph(hCN)	"	β -Ala
15	78	Ac	β -D-2NAL	"	(MeEt) D-Arg	"	Asp
	79	Acr	Pro	"	D-Ser(OtBu)	"	Leu
	80	H	dehydroPro	Abu	(imBzl) D-His	Abu	Val
	81	Bz	(4Br) D-Phe	"	(5Cl) D-Trp	"	Gly
	82	"	D-pGlu	"	(6Br) D-Trp	"	Phe
20	83	For	β -D-1NAL	"	D-Dbu(atz)	"	Cys
	84	"	dehydroPro	"	(Ipr ₂) D-Har	Abu	Orn
	85	Vac	β -D-2NAL	"	D-Pro	"	Lys
	86	"	D-Phe	Asp	D-Ile	Dpr	His
	87	H	dehydroPro	"	D-Aph(chCN)	"	Har

Each of the peptides listed in Table VI is considered effective to block GnRH-induced LH secretion

30 in vitro at a reasonable concentration. All of the peptides are considered to be effective to prevent ovulation of female mammals at low dosages.

-35-

EXAMPLE VII

Peptides as indicated in TABLE VII having the

formula: Ac-dehydroPro-(4Cl)D-Phe- $\overbrace{R_3-R_4}^{R_{11}}$ -Asp- $\overbrace{R_5}^{R_{10}}$ -Leu-Orn-

5 Pro- $\overbrace{R_6}^{R_{10}}$ -NH₂ are prepared by the solid-phase procedure referred to above.

TABLE VII

		R_3	R_4	R_5	R_{10}	R_{11}
10						
	88	(6NO ₂) D-Trp	Asp	D-Aph(2mpCN)	Dpr	Phe
	89	"	"	D-Val	"	Dbu
	90	(6F) D-Trp	"	D-Aph(1CN)	"	Arg
15	91	"	"	D-Nva	"	Dpr
	92	(5OCH ₃) D-Trp	"	D-Har(2mpCN)	"	Val
	93	"	"	D-Dpr(atz)	"	Ala
	94	(1Ac) D-Trp	"	(Me ₂) D-Har	"	Gly
	95	(1For) D-Trp	"	(5CH ₂) D-Trp	"	Cys
20	96	(6Br) D-Trp	Abu	D-Har(1CN)	Abu	Asp
	97	"	"	D-Leu	Abu	Lys
	98	(6CH ₃) D-Trp	"	D-Aph(bzCN)	Abu	Glu
	99	(6NH ₂) D-Trp	Asp	(4NH ₂) D-Phe	Dpr	Gln
25	100	(5NH ₂) D-Trp	"	D-Ala	"	Asn

Each of the peptides listed in Table VII is
 30 considered effective to block GnRH-induced LH secretion
in vitro at a reasonable concentration. All of the
 peptides are considered to be effective to prevent
 ovulation of female mammals at low dosages.

EXAMPLE VIII

Peptides as indicated in TABLE VIII having the

formula:



5 are prepared by the solid phase procedure referred to above.

TABLE VIII


		R_1	R_6	R_7	R_{11}
10	101	β -D-2NAL	(5NO ₂) D-Trp	Leu	Cys
	102	"	D-Har(eCN)	"	Har(eCN)
	103	"	D-Har(hCN)	"	Arg(hCN)
	104	"	(EtBu) D-Arg	"	(4gua) Phe
	105	dehydroPro	D-Aph(atz)	3PAL	(4OCH ₃) Phe
15	106	"	(4NO ₂) D-Phe	Tyr	Arg(iCN)
	107	β -D-2NAL	D-Dpr(atz)	NML	Aph(atz)
	108	"	β -D-1NAL	4PAL	(gua4CH ₂) Phe
	109	"	(imBzl) D-His	Leu	Aph(bCN)
	110	"	(6NO ₂) D-Trp	"	Dpr(atz)
20	111	"	D-Tyr	"	Orn(atz)
	112	"	(1For) D-Trp	Phe	Dbu(atz)
	113	"	(6F) D-Trp	NML	Aph(bzCN)
	114	(C ⁶ Me/ 4Cl) D-Phe	(4Cl) D-Phe	Nle	Orn(atz)
	115	Pro	D-Lys(atz)	Met	Lys(atz)
25	116	dehydroPro	(6OCH ₃) D-Trp	Nva	Dbu(atz)
	117	"	(5CH ₃) D-Trp	"	Dpr
	118	"	(1Ac) D-Trp	(4F) Phe	Aph(iCN)
	119	"	D-Aph(mCN)	NML	Dbu
	120	"	D-Arg(bzCN)	Nle	(4Br) Phe
30	121	"	D-Aph(2mpCN)	Trp	Arg(2mpCN)
	122	D-Pro	(2,4Cl ₂) D-Phe	Nva	Har(bzCN)
	123	β -D-2NAL	D-Aph(atz)	Tyr	Aph(atz)
	124	"	(5Cl) D-Trp	Met	Dpr(atz)
	125	(4Cl) D-Phe	(4Br) D-Phe	3PAL	Arg (acetate salt)

-37-

Each of the peptides listed in Table VIII is considered effective to block GnRH-induced LH secretion in vitro at a reasonable concentration. All of the peptides are considered to be effective to prevent ovulation of female mammals at low dosages.

EXAMPLE IX

Bicyclic peptides as indicated in TABLE IX having the formula:



are prepared by the solid-phase procedure referred to above.

TABLE IX

		n	R ₅	R ₈	R ₁₁
20	126	5	Glu	Dbu	Lys
	127	5	"	"	Orn
	128	3	Hgl	Dpr	(4Cl)Phe
25	129	6	"	"	Arg(iCN)
	130	2	Glu	Dbu	His
	131	5	Hgl	Dpr	Dbu(atz)
	132	3	"	"	Lys(atz)
	133	5	"	Dbu	Arg
30	134	6	Asp	"	(4NO ₂)Phe
	135	2	Glu	"	(gua4CH ₂)Phe
	136	3	"	Dpr	Orn(atz)
	137	5	Hgl	Orn	Lys
	138	3	Asp	"	Har(bCN)

35

-38-

Each of the peptides listed in Table IX is considered effective to block GnRH-induced LH secretion in vitro at a reasonable concentration. All of the peptides are considered to be effective to prevent ovulation of female mammals at low dosages.

The peptides of the invention are often administered in the form of pharmaceutically acceptable, nontoxic salts, or of metal complexes, e.g., with zinc, barium, calcium, magnesium, aluminum or the like (which are considered as addition salts for purposes of this application), or of combinations of the two. Illustrative of such acid addition salts are hydrochloride, hydrobromide, sulphate, phosphate, nitrate, oxalate, fumarate, gluconate, tannate, maleate, acetate, citrate, benzoate, succinate, alginate, malate, ascorbate, tartrate and the like. For example, an aqueous solution of the peptide can be repeatedly treated with 1N acetic acid and then lyophilized to yield the acetic acid salt thereof. If the active ingredient is to be administered in tablet form, the tablet may contain a pharmaceutically-acceptable diluent or excipient which can include a binder, such as tragacanth, corn starch or gelatin, a disintegrating agent, such as alginic acid, and/or a lubricant, such as magnesium stearate. If administration in liquid form is desired, sweetening and/or flavoring may be used as part of the pharmaceutically-acceptable diluent, and intravenous administration in a carrier such as isotonic saline, phosphate buffer solutions or the like may be effected.

The pharmaceutical compositions will usually contain the peptide in conjunction with a conventional, pharmaceutically-acceptable carrier. Usually, the dosage will be from about 10 micrograms to about 2.5 milligrams of the peptide per kilogram of the body weight of the host when given intravenously; although oral dosages will

-39-

be higher, it is anticipated that the cyclic nature of these compounds will permit more effective oral administration. Overall, treatment of subjects with these peptides is generally carried out in the same manner as the clinical treatment using other antagonists of GnRH using a suitable liquid carrier in which the peptide is soluble.


It may also be desirable to deliver the GnRH analog over prolonged periods of time, for example, for periods of one week to one year from a single administration, and slow release, depot or implant dosage forms may be utilized. For example, a dosage form may contain a pharmaceutically acceptable non-toxic salt of the compound which has a low degree of solubility in body fluids, for example, an acid addition salt with a polybasic acid, a salt with a polyvalent metal cation, or combination of two such salts. A relatively insoluble salt may also be formulated in a gel, for example, an aluminum stearate gel. A suitable, slow-release depot formulation for injection may also contain the GnRH analog or a salt thereof dispersed or encapsulated in a slow degrading, non-toxic or non-antigenic polymer such as a polylactic acid/polyglycolic acid polymer, for example, as described in U.S. Pat. No. 3,773,919. These compounds may also be formulated into silastic implants.

These peptides can be administered to mammals intravenously, subcutaneously, intramuscularly, orally, percutaneously, e.g. intranasally, or intravaginally to achieve fertility inhibition and/or control and also in applications calling for reversible suppression of gonadal activity, such as for the management of precocious puberty or during radiation- or chemo-therapy. They are also useful for treatment of steroid-dependent tumors. Effective dosages will vary with the form of administration and the particular species of mammal being


-40-

treated. Certain of these peptides have extremely good solubility characteristics in water and in saline rendering them particularly valuable in this respect. An example of one typical dosage form is a bacteriostatic
 5 water solution containing the peptide, which solution is administered to provide a dose in the range of about 0.1 to 2.5 mg/kg of body weight. Oral administration of the peptide may be given in either solid form or liquid form.

Although the invention has been described with
 10 regard to its preferred embodiments, it should be understood that changes and modifications as would be obvious to one having the ordinary skill in this art may be made without departing from the scope of the invention which is set forth in the claims which are appended
 15 hereto. The art in the design of GnRH antagonists is extremely well developed inasmuch as work has been progressing for some 20 years. Accordingly, although the following three formulae are considered to provide GnRH antagonists having particularly advantageous properties,
 20 as should be clear from the foregoing specification and tables, there are equivalent residues that can be substituted for the residues specified in these formulae while retaining comparable biological potency and many of the advantages of the invention. The three formulae are
 25 as follows:



-41-



Accordingly, GnRH antagonists having such substitutions are considered to be equivalent. Moreover, in addition to the alternative substituents specifically described herein, there are additional minor adaptations that can be also be made to residues in the various positions of the decapeptides. For example, D-2PAL and D-4PAL are considered to be equivalents of D-3PAL. Substituted Phe, such as (4F)Phe, can be used instead of Phe in the 7-position. Substituted D-Phe, such as (4Cl)D-Phe, and other hydrophobic amino acid residues can also be employed in the 1-position, preferably in D-isomer form, and they are considered equivalents of those specified. Shortened forms of Arg having 1 or 2 less CH₂-groups can be employed as a part of the amide cyclizing linkage. Substituted amides can be employed at the C-terminus.

Particular features of the invention are emphasized in the claims which follow.

-42-

WHAT IS CLAIMED IS:

1. A GnRH antagonist peptide having a decapeptide main chain, which peptide is effective to substantially reduce the amount of secretion of LH by the pituitary, said peptide being an analog of mammalian GnRH wherein the C-terminus is amidated, the side chain of the residue in the 4-position is connected by a covalent bond to the residue in the 10-position, and the side chain of the residue in the 5-position and the side chain of the residue in the 8-position are connected by amide linkages to the α -carbon of an α -amino acid residue outside of said main chain.


2. A peptide according to Claim 1 wherein said connection between said 4- and 10-position residues is via a covalent bond between respective side chains thereof.

3. A peptide in accordance with Claim 2 wherein a side chain carboxyl group of said 4-position residue is connected by an amide bond to a side chain amino group of said 10-position residue.

4. A peptide according to Claim 3 wherein said 5-position residue has a side chain carboxyl group and said 8-position residue has a side chain amino group which groups are linked by amide bonds to said α -carbon.


5. A peptide or a nontoxic salt thereof which contains two cyclizing bonds, said peptide having the formula:

-43-



wherein R_4 is Asp or Abu; R_5 is Glu, Hgl or Asp; R_8 is Dbu, Dpr or Orn; R_{10} is Dpr or Abu; and R_{11} is Gly, Ala, Sar, β -Ala, Leu, Asp, Glu, Orn, Lys, Dbu, Dpr, NAL, PAL, (E)Phe, Arg, His, Tyr, Ser, Gln, Har, Asn, Val, Nle, Nva, Ile, Trp, Cys, Cit or UAA; wherein E is gua, NH_2 , guaCH_2 , H, Cl, F, Br, NO_2 , CH_3 , or OCH_3 ; provided however that when R_4 is Abu, R_{10} is Abu; and when R_4 is Asp, R_{10} is Dpr.

6. A peptide according to Claim 5 which peptide has the formula:



wherein R_4 is Asp; R_{10} is Dpr; and R_{11} is Gly, Ala, Sar, β -Ala, NAL, (E)Phe, Arg or His; wherein E is gua, NH_2 , guaCH_2 , H, Cl, F, Br, NO_2 , CH_3 , or OCH_3 .

7. A peptide according to Claim 6 wherein R_5 is Glu and R_8 is Dbu.

8. A peptide according to Claim 7 wherein R_{11} is a basic α -amino acid.




9. A peptide according to Claim 7 wherein R_{11} is Arg or His.

10. A peptide according to Claim 6 wherein R_5 is Asp and R_8 is Orn.

-44-

11. A peptide according to Claim 6 wherein R_5 is Hgl and R_6 is Dpr.

12. A peptide in accordance with Claim 5
5 having the formula:




13. A peptide according to Claim 12 wherein R_{11}
20 is Arg, Har, (gua)Phe, (guaCH₂)Phe or His.

14. A method for regulating the secretion of gonadotropins comprising intravenously, subcutaneously, intramuscularly, orally, percutaneously, or
25 intravaginally administering an amount, which is effective to prevent GnRH-induced LH secretion, of a pharmaceutical composition containing a peptide or a nontoxic salt thereof as defined in Claim 5 plus a pharmaceutically acceptable carrier so as to provide a
30 daily dosage between about 0.1 and about 2.5 milligrams of said peptide per kilogram of body weight.

15. A peptide or a nontoxic salt thereof which contains two cyclizing bonds, said peptide having the
35 formula:

-45-




wherein R_5 is Asp or Glu; R_8 is Dbu or Orn; R_{11} is Gly, Ala, Sar, β -Ala, NAL, (E)Phe, Arg, His or Har; and E is
 5 gua, NH_2 , guaCH_2 or H.

16. A peptide according to Claim 15 wherein R_5 is Glu, R_8 is Dbu, and R_{11} is Arg, Har, (gua)Phe, (guaCH_2)Phe or His.

10


17. A peptide according to Claim 15 having the formula:



15


18. A peptide according to Claim 15 having the formula:

20



25


19. A peptide according to Claim 15 having the formula:




30

-46-

20. A peptide according to Claim 15 having the formula:




21. A peptide according to Claim 15 having the formula:



15 22. A peptide according to Claim 15 wherein R₁₁ is Arg, Gly, β -Ala, Sar, Phe, β -2NAL, His or (4Cl)Phe.

20 23. A process for making GnRH antagonist peptides, which peptides contain cyclizing bonds between the residues Asp-Dpr and R₅-R₆, respectively, and have good solubility in aqueous media, and which peptides have the Formula I:



-47-

or Orn; and R_{11} is Gly, Ala, Sar, β -Ala, Leu, Har, NAL, (E)Phe, Arg or His; and E is gua, NH_2 , $guaCH_2$, H, Cl, F, Br, NO_2 , CH_3 or OCH_3 ; which method comprises

- (a) forming, by solid-phase synthesis on resin support, a first intermediate compound having the formula:




- (b) removing (X^8) by treatment with piperidine and coupling $(X^8)R_{11}(X^9)$ to the side chain of R_8 ;

- (c) coupling R_5 to R_6 to create a second intermediate having the formula:
- $$X^1-R_5(X^4)-R_6(X^4 \text{ or } X^5)-R_7(X^2 \text{ or } X^4 \text{ or } X^7)-R_8-Pro-Dpr(X^{3a})-X^{10};$$
- $$X^8-R_{11}(X^9) \text{ ---}$$

- (d) simultaneously removing (X^4) from R_5 and (X^8) from R_{11} by treatment with piperidine and creating a cyclizing amide bond;

- (e) then continuing solid-phase synthesis on said resin support and forming a third intermediate compound having the Formula II:



- wherein X^1 is hydrogen or an alpha-amino protecting group; X^2 is hydrogen or a protecting group for an indole nitrogen; X^3 and X^{3a} are hydrazine- or acid-labile protecting groups for carboxyl or amino side chains; X^4 is hydrogen or a protecting group for a phenolic hydroxyl group of Tyr; X^5 is hydrogen or a protecting group for a guanidino or imidazole side chain; X^6 is a base-labile protecting group for a carboxyl group; X^7 is a protecting group for Met; X^8 is a base-labile protecting group for an amino moiety; X^9 is hydrogen or X_5 ; and X^{10} is selected from the group consisting of $O-CH_2$ -(resin support) and $-NH$ -(resin support);

-48-

(f) converting (X³) to a hydrazide by treatment with anhydrous hydrazine;

(g) splitting off any remaining protecting groups and cleaving from said resin support by treatment with HF; and

(h) creating a cyclizing bond between Asp and Dpr, by treating with isoamyl nitrite to convert said hydrazide to an azide and then adjusting the pH to about 7.8.

10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/10662

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C07K 7/00, 7/64; A61K 37/00, 37/38

US CL : 530/317, 313, 328; 514/009, 011, 015

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/317, 313, 328; 514/009, 011, 015

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, 5,064,939 (Rivier et al.) 12 November 1991, see entire document.	1-23
A	Journal of Medicinal Chemistry, Volume 34, issued 1991, Theobald, P., "Novel Gonadotropin-Releasing Hormone Antagonists: Peptides Incorporating Modified N-Cyanoguanidino Moieties", pages 2395-2402, see entire document.	1-23

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents		
A document defining the general state of the art which is not considered to be part of particular relevance	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document published on or after the international filing date	X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed	A*	document member of the same patent family

Date of the actual completion of the international search

07 February 1994

Date of mailing of the international search report

17 FEB 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

CAROL A. SALATA

Telephone No. (703) 308-0196